Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. by Dubois, Anne et al.
Model-based analyses of bioequivalence crossover trials
using the stochastic approximation expectation
maximisation algorithm.
Anne Dubois, Marc Lavielle, Sandro Gsteiger, Etienne Pigeolet, France
Mentre´
To cite this version:
Anne Dubois, Marc Lavielle, Sandro Gsteiger, Etienne Pigeolet, France Mentre´. Model-based
analyses of bioequivalence crossover trials using the stochastic approximation expectation max-
imisation algorithm.. Statistics in Medicine, Wiley-Blackwell, 2011, 30 (21), pp.2582-600.
<10.1002/sim.4286>. <inserm-00643832>
HAL Id: inserm-00643832
http://www.hal.inserm.fr/inserm-00643832
Submitted on 22 Nov 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Model-Based Analyses of Bioequivalene Crossover
Trials Using the SAEM Algorithm
Anne Dubois, Mar Lavielle, Sandro Gsteiger, Etienne Pigeolet
and Frane Mentré
INSERM UMR738,University Diderot Paris 7, Paris, Frane, 75018
INRIA Salay, Orsay, Frane, 91400
Modeling and Simulation Department, Novartis Pharma AG, Basel,
Switzerland, CH-4056
email: anne.duboisinserm.fr
Author's Footnote:
Anne Dubois is a PhD student (anne.duboisinserm.fr), INSERM UMR738, Uni-
versity Diderot Paris 7, Paris, Frane, 75018; Mar Lavielle is Professor of Mathe-
matis (mar.laviellemath.u-psud.fr), INRIA Salay, Orsay, Frane, 91400; Sandro
Gsteiger is a Senior Statistial Modeler (sandro.gsteigernovartis.om), and Etienne
Pigeolet is a Senior Expert Pharmaology Modeler (etienne.pigeoletnovartis.om),
Modeling and Simulation Department, Novartis Pharma AG, Basel, Switzerland, CH-
4056; Frane Mentré is Professor of Biostatistis (frane.mentreinserm.fr), INSERM
UMR738, University Diderot Paris 7, Paris, Frane, 75018. The authors thank the
Modeling and Simulation Department, Novartis Pharma AG, Basel, whih supported
by a grant Anne Dubois during this work, and Sigrid Balser from Sandoz Biophar-
maeutial Development, Holzkirhen, Germany who provided the data set used in
the example.
Abstrat
In this work, we develop a bioequivalene analysis using nonlinear mixed eets
models (NLMEM) that mimis the standard non-ompartmental analysis (NCA).
NLMEM parameters, inluding between (BSV) and within subjet (WSV) variabil-
ity, and treatment, period, and sequene eets are estimated. We explain how to
perform a Wald test on a seondary parameter and we propose an extension of the
likelihood ratio test (LRT) for bioequivalene. These NLMEM-based bioequivalene
tests are ompared to standard NCA-based tests. We evaluate by simulation the
NCA and NLMEM estimates, and the type I error of the bioequivalene tests. For
NLMEM, we use the SAEM algorithm implemented in MONOLIX. Crossover trials
are simulated under H0 using dierent numbers of subjets and of samples per sub-
jet. We simulate with dierent settings for BSV and WSV, and for the residual error
variane. The simulation study illustrates the auray of NLMEM-based geometri
means estimated with the SAEM algorithm, whereas the NCA estimates are biased
for sparse design. NCA-based bioequivalene tests show good type I error exept for
high variability. For a rih design, type I errors of NLMEM-based bioequivalene tests
(Wald test and LRT) do not dier from the nominal level of 5%. Type I errors are
inated for sparse design. We apply the bioequivalene Wald test based on NCA and
NLMEM estimates to a three-way rossover trial, showing that Omnitrope
®
powder
and solution are bioequivalent to Genotropin
®
. NLMEM-based bioequivalene tests
are an alternative to standard NCA-based tests. However, aution is needed for small
sample size and highly variable drug.
Keywords: nonlinear mixed eets model; pharmaokinetis; non-ompartmental
bioequivalene analysis; two one-sided tests; Wald test; likelihood ratio test
1 INTRODUCTION
Pharmaokineti (PK) bioequivalene studies are performed to ompare dierent drug
formulations. The most ommonly used design for bioequivalene trials is the two-
period, two-sequene, rossover design. This design is reommended by the Food and
Drug Administration (FDA) (FDA 2001) and the European Mediines Evaluation
Ageny (EMEA) (EMEA 2001). FDA and EMEA reommend to test bioequivalene
from the ratios of the geometri means of two parameters: the area under the urve
(AUC) and the maximal onentration (Cmax) estimated by non-ompartmental anal-
ysis (NCA) (Gabrielson and Weiner 2006). As speied in the regulatory guidelines,
the bioequivalene analysis should take into aount soures of variation that an
be reasonably assumed to have an eet on the endpoints AUC and Cmax. There-
fore, linear mixed eets models (LMEM) inluding treatment, period, sequene, and
subjet eets are usually used to analyse the log-transformed individual parameters
(Haushke et al. 2007). Bioequivalene tests are then performed on the estimates of
the treatment eet.
NCA requires few hypotheses but a large number of samples per subjet (usually be-
tween 10 and 20). PK data an also be analysed using nonlinear mixed eets models
(NLMEM). This method is more omplex than NCA but has several advantages: it
takes advantage of the knowledge aumulated on the drug and an haraterize the
PK with few samples per subjet. This allows one to perform analyses in patients, the
target population, in whom pharmaokinetis an be dierent from healthy subjets.
In a previous work, Dubois et al (Dubois et al. 2010) ompared the standard analysis
of bioequivalene rossover trials based on NCA to the same usual analysis based
on individual empirial Bayes estimates (EBE) obtained by NLMEM. PK data of
eah treatment group were analysed separately using NLMEM. Linear mixed eets
models were then performed on individual AUC and Cmax derived from the EBE.
However, this methodology annot be performed when the EBE shrinkage is above
20%. Panhard and Mentré (Panhard and Mentré 2005) developed dierent ompari-
son and bioequivalene tests based on NLMEM for the analysis of PK rossover trials
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omparing two treatments. For omparison tests, they proposed both the Wald test
and the likelihood ratio test (LRT). For bioequivalene tests, they proposed the Wald
test but the LRT was not developed, due to the omposite null hypothesis. They
applied these tests to two-period, one-sequene, rossover trials. In a later work,
Panhard et al (Panhard et al. 2007) demonstrated the importane of modelling the
between-subjet (BSV) and within-subjet (WSV) variability to ontrol the ination
of the type I error using the same sets of simulations as previously. In both simulation
studies, the NLMEM-based bioequivalene Wald test was performed on AUC only
beause Cmax was a seondary parameter of the PK model, as often in PK modelling.
The use of NLMEM is still rare to analyse bioequivalene rossover trials. Indeed,
there are few published studies whih use NLMEM to analyse bioequivalene trials
(Kaniwa et al. 1990; Pentikis et al. 1996; Combrink et al. 1997; Maier et al. 1999; Hu
et al. 2003; Zhou et al. 2004; Fradette et al. 2005; Zhu et al. 2008). Seven of these
studies are previous to the dierent simulation studies (Kaniwa et al. 1990; Pentikis
et al. 1996; Combrink et al. 1997; Maier et al. 1999; Hu et al. 2003; Zhou et al. 2004;
Fradette et al. 2005). In six of these studies (Kaniwa et al. 1990; Pentikis et al. 1996;
Combrink et al. 1997; Maier et al. 1999; Hu et al. 2003; Fradette et al. 2005), bioe-
quivalene Wald tests were performed on treatment eets estimated by NLMEM,
as Panhard et al. However, all of these applied works used dierent statistial ap-
proahes. The addition of the treatment eet on dierent PK parameters was not
always justied. Only Hu et al (Hu et al. 2003) performed bioequivalene test on
average AUC and Cmax obtained from the xed eet estimates using Monte Carlo
simulation. Finally, none estimated the WSV or adds period or sequene eets as
reommended in the guidelines. There is urrently no published simulation study or
applied work whih takes into aount treatment, period, sequene eets, BSV, and
WSV for the bioequivalene analysis of rossover trials by NLMEM.
In the dierent NLMEM-based bioequivalene analysis, NLMEM parameters were es-
timated by maximum likelihood. Exept for the simulation by Dubois et al (Dubois
et al. 2010), an algorithm based on a rst-order linearization was used, most often the
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First-Order Conditional Estimation (FOCE) algorithm (Lindstrom and Bates 1990).
The FOCE algorithm is a widely used algorithm and orresponds to the industry
standard for model-based PK analyses. Yet, this linearization-based method annot
be onsidered as fully established theoretially. For instane, Vonesh (Vonesh 1996)
and Ge et al (Ge et al. 2004) gave examples of spei designs resulting in inonsis-
tent estimates, suh as when the number of observations per subjet does not inrease
faster than the number of subjets or when the variability of random eets is too
large. Several estimation methods of maximum likelihood theory have been proposed
as alternatives to linearization algorithms like the adaptative gaussian quadrature
(AGQ) method (Pinheiro and Bates 1995) or methods derived from the Expetation-
Maximisation (EM) algorithm (Dempster et al. 1977). The AGQ method requires
a suiently large number of quadrature points implying an often slow onvergene
and is limited to a small number of random eets. Monte Carlo EM algorithms
as proposed by Wei and Tanner (Wei and Tanner 1990), Walker (Walker 1996), or
Wu (Wu 2004) are very time-onsuming in omputation sine they require a huge
amount of simulated data. Alternatively, Delyon et al (Delyon et al. 1999) intro-
dued a stohasti approximation version of the EM algorithm (SAEM), whih is
more eient in terms of omputation. Later, Kuhn and Lavielle (Kuhn and Lavielle
2004) developed an algorithm whih ombined the SAEM algorithm with a Monte-
Carlo proedure. They showed the good statistial onvergene properties of this
algorithm. Reently, Panhard and Samson (Panhard and Samson 2009) developed
an extension of the SAEM algorithm for NLMEM inluding the estimation of the
within-subjet variability.
The main objetive of this work is to develop a bioequivalene analysis based on
NLMEM that mimis the standard bioequivalene analysis performed on NCA esti-
mates. To do so, we use a NLMEM inluding treatment, period, sequene eets,
BSV, and WSV. We also explain how to perform a Wald test on a seondary pa-
rameter of the model (like Cmax), and we propose an extension of the LRT for bioe-
quivalene. These NLMEM-based bioequivalene tests are ompared to standard
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NCA-based tests. We evaluate by simulation the NCA and NLMEM estimates, and
the type I errors of the dierent bioequivalene tests. We use the same sets of sim-
ulations than the previous study by Dubois et al (Dubois et al. 2010) whih allows
to ompare the results. As in Dubois et al, we use dierent sampling designs and
levels of variability, investigating their inuene on the results of the bioequivalene
tests. To estimate NLMEM parameters, we use the SAEM algorithm implemented
in MONOLIX. Then, we apply the Wald test based on NCA and NLMEM estimates
to a three-way rossover trial omparing three formulations of somatropin. A so-
matropin is a biosyntheti version of human growth hormone (hGH) synthesised in
bateria modied by the addition of the gene for hGH. Replaement therapy with
somatropin is a well aepted, eetive treatment for hGH deieny in hildren and
adults (Faui et al. 2008).
In Setion 2 of this paper, we desribe the LMEM for NCA estimates, the NLMEM
on onentrations, and the bioequivalene tests based on both approahes. In Se-
tion 3, we present the simulation study, the estimation, and the evaluation of the
estimates and of the type I errors. We present the example in Setion 4, followed by
a disussion in Setion 5.
2 MODELS AND BIOEQUIVALENCE TESTS IN CROSSOVER
TRIALS
In the following, we onsider rossover pharmaokineti trials with C treatments, K
periods, and Q sequenes.
2.1 Models
Linear Mixed Eets Model for NCA
The standard bioequivalene analysis reommended by FDA and EMEA (FDA
2001; EMEA 2001) is based on NCA individual estimates of AUC and Cmax. We
dene θikl the l
th
individual parameter (AUC if l = 1 or Cmax if l = 2) for subjet
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i (i = 1, · · · , N) at period k (k = 1, · · · , K). The individual parameters are log-
transformed and analysed using a linear mixed eets model written as follows:
log(θikl) = νl + β
T ′
l
Tik + β
P ′
l
Pk + β
S ′
l
Si + ηil + ǫikl (1)
where νl is the expeted value orresponding to the ombination of ovariate refer-
ene lasses. βT
l
, βP
l
, and βS
l
are the vetors of oeients of treatment, period, and
sequene eets for the lth individual parameter (AUC or Cmax). Tik, Pk, Si are the
known vetors of treatment, period, and sequene ovariates of size C, K, and Q,
respetively. Tik is omposed of zeros exept for the c
th
element (c = 1, · · · , C) whih
is one when treatment c is given to patient i at period k. Similarly, Pk and Si are
omposed of zeros exept for the kth and qth elements (k = 1, · · · , K, q = 1, · · · , Q)
whih are one. We onsider that the rst treatment, period, and sequene are the
referene lasses. The rst elements of βT
l
, βP
l
, and βS
l
are xed to zero, and other
omponents are estimated. It is assumed that the random subjet eet ηil and the
residual error ǫikl are independently normally distributed with zero mean.
Nonlinear Mixed Eets Modelling
We denote by yijk the onentration for subjet i (i = 1, · · · , N) at sampling time
j (j = 1, · · · , nik) for period k (k = 1, · · · , K). We dene f to be the nonlinear phar-
maokineti funtion whih links onentrations to sampling times. The nonlinear
mixed eets model an be written as:
yijk = f(tijk,ψik) + g(tijk,ψik) ǫijk (2)
with ψik the p-vetor of pharmaokineti parameters of subjet i for period k.
g(tijk,ψik) ǫijk is the residual error where ǫijk is a Gaussian random variable with
zero mean and variane one. All ǫijk are independent and identially distributed.
We onsider a ombined error model, additive plus proportional, with g(tijk,ψik) =
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a+ bf(tijk,ψik).
The statistial model used for the individual parameters ψik is derived from the lin-
ear mixed eets model used to analyse the NCA individual estimates. So, the lth
omponent of ψik is dened as:
log(ψikl) = log(λl) + β
T ′
l
Tik + β
P ′
l
Pk + β
S ′
l
Si + ηil + κikl (3)
with λ = (λl; l = 1, · · · , p) the p-vetor of xed eets for the ovariate referene
lasses. The known vetors of the treatment, period, and sequene ovariates, Tik,
Pk, and Si, are dened as for NCA (setion 2.1). β
T
l
, βP
l
, and βS
l
are the vetors of
oeients of treatment, period, and sequene eets for the lth PK parameter. As
previously mentioned, we onsider that the rst treatment, period, and sequene are
the referene lasses. The rst elements of βT
l
, βP
l
, and βS
l
are xed to zero, and other
omponents are estimated. ηi = (ηil; l = 1, · · · , p) is the vetor of random eets of
subjet i orresponding to the between-subjet variability. κik = (κikl; l = 1, · · · , p)
is the vetor of random eets of subjet i at period k orresponding to the variability
between periods of treatment for the same individual, or within-subjet variability.
These random eets are assumed to be normally distributed with zero mean and
ovariane matrix of size p×p named Ω and Γ, respetively. We dene ω2l and γ2l the
variane for BSV and WSV of the lth parameter, orresponding to the lth element of
the diagonal of Ω and Γ. ηi, κik, and ǫijk are assumed to be mutually independent.
Finally, the unknown population parameters of the statistial model are the xed
eets ("referene" and ovariate eets) and the variane parameters (Ω, Γ, a, b).
2.2 Two-One Sided Tests
The bioequivalene test is performed on the cth treatment eet of the lth param-
eter, βTc,l (c = 2, · · · , C and l = 1, 2 for NCA or l = 1, · · · , p for NLMEM). Its null
hypothesis is H0: {βTc,l ≤ −δ or βTc,l ≥ δ} whih is deomposed in two one-sided hy-
potheses H0,−δ: {βTc,l ≤ −δ} and H0,δ: {βTc,l ≥ δ}. The bioequivalene test is based
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on Shuirmann's two one-sided tests (TOST) proedure (Shuirmann 1987). H0,−δ
and H0,δ are tested separately by a one-sided test. The global null hypothesis H0
is rejeted with a type I error α if both one-sided hypotheses are rejeted with a
type I error α. The p-value of the TOST is the maximum of both p-values of the
one-sided tests. The major issue of a bioequivalene test is to dene δ. To assess
pharmaokineti bioequivalene, the guidelines (FDA 2001; EMEA 2001) reommend
δ = log(1.25) ≈ 0.22 (i.e. −δ = log(0.8)) for log(AUC) and log(Cmax). Due to the
linear model on log-parameters, these bounds orresponds to 80%-125% on the pa-
rameter sale.
Wald Tests Based on NCA Estimates
In the following, we all se(βTc,l) the standard error of the treatment eet estimate
β̂Tc,l. We also dene W−δ = (β̂
T
c,l + δ)/se(β
T
c,l) and Wδ = (β̂
T
c,l − δ)/se(βTc,l), the two
Wald statistis for the one-sided hypotheses H0,−δ and H0,δ, respetively. For the
standard NCA-based bioequivalene analysis, we assume that W−δ and Wδ follow a
Student t-distribution with df degrees of freedom under H0,−δ and H0,δ, respetively.
The global null hypothesis H0 is rejeted with a type I error α if W−δ ≥ t1−α(df) and
Wδ ≤ −t1−α(df), where t1−α(df) is the (1− α) quantile of the Student t-distribution
with df degrees of freedom. For balaned datasets (i.e. with N subjets for eah
period), df = N − 2 (Haushke et al. 2007; Chow and Liu 2000). An alternative ap-
proah to perform a bioequivalene test is to ompute the (1−2α) ondene interval
(CI) of β̂Tc,l. H0 is rejeted if this (1− 2α) CI lies within [−δ; δ].
Wald Test Based on NLMEM Estimates
For the bioequivalene Wald test using NLMEM estimates, we use a very simi-
lar approah to NCA-based bioequivalene Wald test. Same notations are used for
NLMEM-based analyses as for NCA. For NLMEM, we assume that W−δ and Wδ
follow a Gaussian distribution under H0,−δ and H0,δ, respetively. The global null
hypothesis H0 is rejeted with a type I error α if W−δ ≥ z1−α and Wδ ≤ −z1−α,
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where z1−α is the (1−α) quantile of the standard normal distribution. The rejetion
of H0 an also be based on the (1− 2α) CI as desribed previously (setion 2.2).
To mimi the standard bioequivalene analysis, we would like to perform the NLMEM-
based bioequivalene Wald test on AUC and Cmax whih are often seondary pa-
rameters of the PK model. So, we propose an approah to perform the NLMEM-
based bioequivalene Wald on a seondary parameter. A seondary parameter is a
funtion of the PK parameters of the strutural model. Its cth treatment eet is
βTc,SP = h(λ,β
T
c
) with h the funtion linking βTc,SP to the PK parameters, λ the refer-
ene eets, and βT
c
the cth treatment eets. To perform a bioequivalene Wald test
on the cth treatment eet of a seondary parameter, βTc,SP and its standard error,
se(βTc,SP ), should be estimated. By denition, β̂
T
c,SP = h(λ̂, β̂
T
c
). However, se(βTc,SP )
annot be diretly omputed as h is usually a nonlinear funtion. We propose to
approximate it using the delta method (Oehlert 1992) or simulations. For the delta
method, we use the partial derivatives of h, the xed eet estimates (λ̂,β̂T
c
), and
their estimated ovariane matrix Σ̂, whih is a submatrix of the inverse of the Fisher
information matrix estimate: se(βTc,SP ) =
√
∇h(λ̂, β̂T
c
)′ Σ̂ ∇h(λ̂, β̂T
c
). To estimate
se(βTc,SP ) by simulations, we simulate β
T
c,SP Ns times using a Gaussian distribution
with mean the xed eet estimates (λ̂,β̂T
c
) and ovariane matrix Σ̂. Then, se(βTc,SP )
is estimated as the standard deviation of the Ns simulated β
T
c,SP .
Likelihood Ratio Test Based on NLMEM Estimates
There is no simple extension of the likelihood ratio test for the omposite null hy-
pothesis of a bioequivalene test. Therefore, for a parameter of the PK model, we
develop a methodology to perform a NLMEM-based bioequivalene LRT based on
prole likelihood methods (Bates and Watts 1988; Meeker and Esobar 1995). Let
us dene Mall to be the NLMEM where all xed eets are estimateed and Mδ,c,l the
NLMEM where βTc,l is xed to δ and all other parameters (inluding the other ompo-
nents of βT
l
) are estimated. The proposed approah test whether the likelihood-based
ondene interval of β̂Tc,l lies within [−δ; δ]. To do so, we perform two "one-sided"
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LRT taking into aount β̂Tc,l estimated with Mall, and the estimation of the log-
likelihood of three models Mall, M−δ,c,l, and Mδ,c,l. We dene the statisti Λδ,c,l as
follows: Λδ,c,l = −2 × (Lδ,c,l − Lall) with Lall and Lδ,c,l the estimated log-likelihoods
for the models Mall and Mδ,c,l, respetively. The null hypothesis H0,−δ is rejeted
with a type I error α if Λ−δ,c,l ≥ χ21(1 − 2α) and −δ < β̂Tc,l, where χ21(1 − 2α) is the
(1− 2α) quantile of the Chi-squared distribution with one degree of freedom. H0,δ is
rejeted if Λδ,c,l ≥ χ21(1 − 2α) and β̂Tc,l < δ. Consequently, the global null hypothesis
H0 is rejeted with a type I error α if −δ < β̂Tc,l < δ and Λ−δ,c,l ≥ χ21(1 − 2α) and
Λδ,c,l ≥ χ21(1− 2α).
3 SIMULATION STUDY
3.1 Simulation Settings
We use the onentration data of the anti-asthmati drug theophylline to dene the
population PK model for the simulation study. These data are lassial in population
pharmaokinetis (Pinheiro and Bates 2000) and have been used in previous simu-
lation studies (Panhard and Mentré 2005; Panhard et al. 2007; Dubois et al. 2010).
We assume that onentrations an be desribed by a one-ompartment model with
rst-order absorption and rst-order elimination:
f(t, ka, CL/F, V/F ) =
FDka
CL− V ka (exp(−ka t)− exp(−CL/V t)) (4)
where D is the dose, F the bioavailability, ka the absorption rate onstant, CL the
learane of the drug, and V the volume of distribution.
We simulate two-treatment, two-sequene, rossover trials with two or four periods.
For eah two-period trial, the N/2 subjets of the rst sequene reeive the referene
treatment (Ref ) and the test treatment (Test) in period one and two, respetively.
The other N/2 subjets alloated to the seond sequene reeive treaments in the
reverse order. For eah four-period trial, the N/2 subjets of the rst sequene re-
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eive the treatment Ref in periods one and three, and the treatment Test in periods
two and four. The N/2 subjets of the seond sequene reeive the treament Test in
periods one and three, and the treatment Ref in periods two and four.
We onsider that sampling times are similar for all subjets and all periods. So,
j = 1, · · · , n, where n is a xed number of sampling times for eah simulated sam-
pling design. We use four dierent sampling designs, whih are also used by Dubois
et al (Dubois et al. 2010). We simulate with the original design with N = 12 subjets
and n = 10 samples per subjet and per period, taken at the times of the initial
study (0.25, 0.5, 1, 2, 3.5, 5, 7, 9, 12, and 24 h after dosing). We also simulate with
an intermediate design with N = 24 subjets and n = 5 samples, taken at 0.25, 1.5,
3.35, 12, and 24 h after dosing, a sparse design with N = 40 subjets and n = 3
samples, taken at 0.25, 3.35, and 24 h after dosing, and a rih design N = 40 subjets
and n = 10 samples, taken at the times of the initial study.
For the simulation study, we assume that α = 5% and δ = log(1.25). We x the
dose to 4 mg for all subjets. The vetor of population parameters λ is omposed of
λka = 1.48 h
−1
, λCL/F = 40.36 mL/h, and λV/F = 0.48 L for the referene treatment.
We assume that the bioavailability hanges between treatments, i.e., we assume the
same modiation for CL/F and V/F . It also similarly aets both seondary pa-
rameters AUC and Cmax with AUC = FD/CL and Cmax dened in Equation 5 of
the Appendix. In the following, as we onsider only two treatments in the simula-
tion study, we omit the subsript c; we dene βTCL/F and β
T
V/F the treatment eet on
CL/F and V/F for the treatment Test (βTka = 0). As suggested by Liu and Weng (Liu
and Weng 1995), the type I error of the bioequivalene test an be evaluated for eah
boundary of H0 spae, i.e., log(0.8) and log(1.25). Consequently, we simulate under
two dierent hypotheses: βTCL/F = β
T
V/F = log(0.8) and β
T
CL/F = β
T
V/F = log(1.25)
whih are the boundaries of H0,log(0.8) and H0,log(1.25), respetively. In the following,
we all H0;80% and H0;125% these two simulated hypotheses. We assume no period
eet or sequene eet, and Ω and Γ are diagonal.
We simulate with two levels of variability for the between-subjet and within-subjet
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variability. For the low level of variability, we x ωka and ωCL/F to 0.2, and ωV/F to
0.1; γka, γCL/F and γV/F are xed to half BSV for the three parameters. For the high
level, we x the three standard deviations to 0.5 for BSV, and 0.15 for WSV. We also
simulate with two levels of variability for the residual error: a = 0.1 mg/L, b = 0.10
for the low level, and a = 1 mg/L, b = 0.25 for the high level. The high level of
residual error is only used with the high level of BSV and WSV. We all Sl,l the
variability setting with low variability for BSV, WSV, and for the residual error. Sh,l
is the variability setting orresponding to high variability for BSV, WSV, and low for
the residual error. Finally, Sh,h is the variability setting with high variability for BSV,
WSV, and for the residual error. In the following, we all a simulation setting the
assoiation of one design with one variability setting and one simulated hypothesis.
We simulate rossover trials with 2 periods under H0;80% and H0;125%. In that ase,
for eah sampling design, we simulate using the variability settings Sl,l and Sh,l. We
simulate using Sh,h only for the intermediate design. We simulate rossover trials
with 4 periods under H0;80% using rih and sparse sampling designs, and the two
variability settings Sl,l and Sh,l. All simulations are performed using the statistial
software R 2.7.1. We use the funtion rmvnorm of the pakage mvtnorm, whih is a
pseudorandom number generator for the multivariate normal distribution. For eah
simulated trial, we speify the seed using the funtion set.seed in order to make
simulations reproduible.
3.2 Estimation
NCA
As in Dubois et al (Dubois et al. 2010), we estimateAUC and Cmax by non ompart-
mental analysis (Gabrielson and Weiner 2006) using a R funtion whih we develop.
For a rossover trial, this funtion provides the estimation of dierent NCA param-
eters for eah subjet and eah treatment group. In this study, we use the linear
trapezoidal rule to ompute the AUC0−last between the time of dose (equal to 0) and
the last sampling time. To obtain the total AUC (between the time of dose and in-
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nity), we estimate the terminal slope equal to CL/V using the logarithm of the last
onentrations to perform a log-linear regression. To do so, we use a xed number
of onentrations whih depends on the number of samples per subjet in the design.
For the original and rih designs where n = 10, we use the last four onentrations
whih orrespond to sampling times 7, 9, 12 and 24 h. For intermediate and sparse
designs where n = 5 and n = 3 respetively, we use the last two onentrations whih
orrespond to sampling times 12 and 24 h for the intermediate design, and to 3.35
and 24 h for the sparse design. For all designs, Cmax is estimated as the maximal
observed onentration.
The analysis of log parameters by LMEM is then performed using the R funtion
lme from the pakage nlme. For the estimation of LMEM parameters (inluding the
treatment eet and its SE), the restrited maximum likelihood (REML) preoedure
is used, as reommended in the guidelines (FDA 2001; EMEA 2001). For the original
design where N = 12, df = 10. For the rih and sparse design where N = 40, df = 38.
For the intermediate design where N = 24, df = 22.
All omputations inluding the dataset simulation, the estimation by NCA, and the
standard bioequivalene analysis by LMEM are made under R 2.7.1. The dierent R
sripts are available upon request to the orresponding author.
NLMEM
We estimate the NLMEM parameters (inluded treatment, period, sequene eets,
BSV and WSV) by maximum likelihood using the SAEM algorithm (Panhard and
Samson 2009) implemented in MONOLIX (Lavielle et al. 2010). Estimation of stan-
dard errors (SE) and log-likelihood are also needed to perform Wald and likelihood
ratio tests, respetively. SE an be evaluated as the square root of the diagonal ele-
ments of the inverse of the Fisher information matrix estimate whih has no analyti
form. In MONOLIX, one method to evaluate this matrix is to derive an approximate
expression by the linearization of the funtion f around the onditional mean of the
individual parameters obtained with the SAEM algorithm. Although linearization-
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based algorithms are not reommended to estimate NLMEM parameters, satisfatory
results for SE estimation have been shown using this approah for omputation of
the FIM (Bazzoli et al. 2009). There is no analytial expression of the likelihood in
NLMEM. In MONOLIX, it is proposed to estimate the log-likelihood of the obser-
vations without approximation using the Importane Sampling (IS) method (Kuhn
and Lavielle 2005; Samson et al. 2007). The IS method is a Monte-Carlo proedure
where individual parameters are simulated at eah iteration using an instrumental
distribution adequately hosen to redue the variane of the estimator.
NLMEM parameters, standard errors and log-likelihoods are estimated with MONO-
LIX 2.4., supported by MATLAB R2007a. The use of MONOLIX software for the
analysis of rossover bioequivalene trials is explained in a online Supplementary Ma-
terial
1
.
3.3 Evaluation Methods
Estimates
The SAEM algorithm used for the estimation of NLMEM parameters has not been
evaluated for models inluding treatment, period, sequene eets, BSV, and WSV.
Therefore, we evaluate the SAEM algorithm for two and four-period rossover trials
with the rih and sparse design. We use the H0;80% simulation settings of the two
variability settings Sl,l and Sh,l. There are 8 dierent simulation settings used (2 or
4 periods, rih or sparse design, Sl,l or Sh,l variability). We t the statistial model
Mall for the 1000 trials of eah simulation setting of both types of rossover trials (2
or 4 periods). Then, for the 1000 repliates, we ompute the bias and the root mean
square error (RMSE) for eah estimated parameter.
Furthermore, in the standard bioequivalene analysis, the geometri means of AUC
and Cmax are reported for eah treatment group. We evaluate those estimates for
the referene treatment, and for NCA and NLMEM. We also evaluate the treatment
eet estimates for AUC and Cmax, and for NCA and NLMEM. Lastly, good estima-
1
Supporting information may be found in the online version of this artile.
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tion of the standard error is important when performing Wald tests. So, we evaluate
the SE of the treatment eet estimates, for NCA and NLMEM. To evaluate the
geometri means, the treatment eets, and their SE we use the two-period rossover
trials simulated under the null hypothesis H0;80% with the four dierent sampling
designs (rih, original, intermediate and sparse), and the three variability settings
(Sl,l, Sh,l and Sh,h). There are 9 dierent used simulation settings, 4 for Sl,l and Sh,l,
and 1 for Sh,h where only the intermediate design is simulated. For NCA, for eah
simulated trial, the geometri mean of AUC (Cmax) for the referene treatment is
omputed from the N individual estimated AUC (Cmax). For NLMEM, due to the
log-normal distribution of the random eets, the xed eet estimates for the refer-
ene lasses orrespond to the geometri mean estimates for the referene treatment.
So, the NLMEM-based geometri mean of AUC for the referene treatment is diretly
obtained from the learane estimate as AUC = FD/CL. For Cmax, the geometri
mean is omputed from the xed eet estimates using Equation 5 of the Appendix.
For NCA and NLMEM estimates, the geometri means are ompared to the AUC or
Cmax omputed from the NLMEM simulated parameters. For NCA, the treatment
eet on AUC and Cmax are estimated by LMEM as explained in setion 2.1. For
NLMEM, due to the linear ovariate model on log-parameters, β̂TAUC = −β̂TCL/F . The
treatment eet β̂TCmax is omputed from λ̂ and β̂
T
using Equation 6. For NCA and
NLMEM estimates, the treatment eet estimates are ompared to the simulated
value of the treatment eet. For NCA, standard errors of the treatment eet are
estimated by LMEM. For NLMEM, as β̂TAUC = −β̂TCL/F , their standard error are
equal. The SE of β̂TCmax is estimated by the delta method and simulations (with
Ns = 10000). For the delta method, the expression and details are given in the
Appendix. The estimated standard errors of the treatment eet are ompared to
the orresponding empirial standard error for NCA and NLMEM estimates. For
one simulation setting and one approah (NCA or NLMEM), the empirial standard
error is omputed as the standard deviation of the 1000 treatment eet estimates.
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Type I Error
To evaluate the type I error of the bioequivalene tests, we use the two-period
rossover trials simulated with the four dierent sampling designs, both hypotheses
and the three variability settings. There are 18 dierent simulation settings used, 8
for Sl,l and Sh,l, and 2 for Sh,h where only the intermediate design is simulated. The
simulation settings under H0;80% are also used to evaluate the estimates of AUC and
Cmax (setion 3.3).
We perform the bioequivalene Wald test based on NCA estimates on AUC and Cmax.
For NLMEM, tests on CL/F and AUC are equivalent beause β̂TAUC = −β̂TCL/F and
se(βTAUC) = se(β
T
CL/F ). So, the NLMEM-based bioequivalene Wald test and LRT
are performed on AUC. As Cmax is a seondary parameter of the NLMEM, only
the NLMEM-based Wald test is performed on this parameter, and not the LRT. For
NLMEM, the treatment eet β̂TCmax is omputed from λ̂ and β̂
T
. Its standard error
is estimated both by the delta method and by simulations (with Ns = 10000). For
AUC and Cmax, the NLMEM-based bioequivalene Wald test is performed using esti-
mated and empirial SE. For Cmax, it is performed using estimated SE obtained from
the delta method and simulations, for omparison. For eah one-sided hypothesis
H0;80% and H0;125%, the type I error is estimated by the proportion of the simulated
trials for whih the null hypothesis H0 is rejeted. The global type I error is dened
as the maximum value of both estimated type I errors (Dubois et al. 2010; Panhard
and Mentré 2005). For 1000 repliates, the 95% predition interval (95% PI) for a
type I error of 5% is [3.7%; 6.4%].
3.4 Results
Evaluation of the Estimates
For the evaluated settings, all NLMEM parameters inluding treatment, period,
sequene eets are estimated by the SAEM algorithm. Boxplots of the estimates of
the learane referene eet, the orresponding ovariate eets and the standard
deviations of BSV and WSV are displayed in Figure 1. For the six parameters and
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both variability settings, the distribution is narrower when the number of samples or
periods inreases. For all simulation settings of both types of trials, the median of the
xed eets is lose to the orresponding simulated value. For BSV and WSV, the
median of the estimates is loser to the simulated value for four-period trials than for
two-period trials. For the variability setting Sh,l, BSV and WSV are slightly under-
estimated espeially for the sparse design. Similar results (not shown) are obtained
for both PK parameters, ka and V/F . Table 1 provides the bias (×100) and RMSE
(×100) of estimates of the referene eets and the standard deviations for BSV,
WSV, and residual error. For all simulation settings and both types of rossover tri-
als (2 or 4 periods), there is no bias and RMSE are small for the referene eets and
the residual error. For BSV and WSV, bias dereases when the number of samples
inreases. For all parameters, RMSE derease when the number of samples inreases.
Furthermore, RMSE are smaller for Sl,l than for Sh,l and smaller for four-period tri-
als than for two-period trials. The same observations are made for ovariate eets
(results not shown).
For eah simulation setting of two-period rossover trials of the hypothesis H0;80% and
for NCA and NLMEM, boxplots of the referene treatment geometri mean estimates
of AUC and Cmax are displayed in Figure 2. For AUC and Cmax, and for NCA and
NLMEM estimates, the distribution is narrower when the variability is smaller. For
NCA estimates, the median of the estimates is loser to the true simulated mean
for the rih design, and there is a lear and very large bias of the geometri mean
estimates for sparse design. For NLMEM estimates, the median of the estimates is
lose to the true simulated mean for all simulation settings. Figure 3 displays the
boxplot of the treatment eet estimates on AUC and Cmax and their standard er-
rors for NCA and NLMEM estimates. The standard errors se(βTCmax) are estimated
by the delta method, and very similar results are obtained by simulations. For NCA
and NLMEM, for both parameters and all simulation settings, the median of the esti-
mated treatment eets is lose to the simulated value. Furthermore, the distribution
is narrower when the variability dereases or when the number of subjets inreases.
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The distribution of the estimated standard errors is narrower and the empirial stan-
dard error is smaller when the variability dereases or when the number of subjets
inreases. For both parameters, the median of the estimated standard error is loser
to the empirial one when the variability dereases. For the original design under
Sh,l and the intermediate design under Sh,h, standard errors of both parameters are
underestimated for NCA and NLMEM estimates.
Evaluation of the Type I Error
Table 2 provides type I errors of bioequivalene tests performed on the treatment
eets of AUC, and Cmax for eah one-sided hypothesis and eah sampling design of
two-period rossover trials. Mostly, for all tests and both parameters, type I errors
of both hypotheses are lose. Only the type I errors for Cmax and the Sh,h setting
are somewhat dierent. For Wald tests based on NCA estimates, and for Sl,l and Sh,l
settings, type I errors do not dier from the nominal level of 5%. For Sh,h setting,
the type I errors are muh too onservative for AUC, and are inated for Cmax. For
the NLMEM-based Wald test, type I errors for Cmax using SE obtained by the delta
method or simulations are idential. For AUC, type I errors of the NLMEM-based
Wald test are lose to type I errors of the LRT. For the rih design (N = 40, n = 10),
type I errors of both tests do not dier from the nominal level of 5%. However, for
eah simulation setting, there is an inrease of the type I error of both tests when the
number of subjets and/or the number of samples dereases.
The left hand side of Figure 4 displays the global type I error for AUC (top) and
Cmax (bottom) versus the design for eah variability setting for the Wald test based
on NCA estimates. For both parameters, the global type I error lies in the 95%PI of
the nominal level for all the designs of Sl,l and Sh,l settings. For the Sh,h setting, it
is too onservative for AUC and inated for Cmax. The right hand side of Figure 4
displays the global type I error of the NLMEM-based Wald test using the estimated
or empirial standard error, and the NLMEM-based LRT. For the Wald tests using
estimated SE and LRT, and for both parameters, the global type I error lies in the
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95%PI of the nominal level for the rih design. It inreases when the number of
subjets or the number of samples dereases and is lower for Sl,l than for Sh,l.For
the NLMEM-based Wald test using the empirial SE, it an be seen that for both
parameters the global type I errors almost never dier from the nominal level of 5%
showing the inuene of the underestimation of the standard errors on the properties
of the NLMEM-based Wald test.
4 APPLICATION
In 2005, somatropins available in the United States (and their manufaturers) in-
luded Nutropin
®
(Genenteh), Humatrope
®
(Lilly), Genotropin
®
(Pzer), Norditro-
pin
®
(Novo), and Saizen
®
(Merk Serono). In 2006, the FDA approved a new somat-
ropin alled Omnitropee
®
(Sandoz). For this approval, bioequivalene rossover trials
were performed. We analyse one of them with the standard NCA-based approah and
the proposed NLMEM-based approah. Then, we perfom the bioequivalene Wald
test using NCA and NLMEM estimates.
4.1 Material and methods
A randomized, double-blind, single-dose, 3-way rossover study with three treat-
ments, three periods, and six sequenes was onduted to ompare the pharmaoki-
neti parameters of Omnitrope
®
powder for solution for injetion, Omnitrope
®
3.3
mg/mL solution for injetion, and Genotropin
®
powder for solution after a single sub-
utaneous dose of 5 mg. Thirty-six healthy auasian adults were reruited and they
reeived otreotide for endogenous hGH suppression before eah treatment period.
The three treatment periods were separated by a seven day wash-out period. Blood
samples for pharmaokineti assessments were olleted after dose administration for
eah period at times 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24 h. Conentrations were
measured by hemiluminesent immunometri assay (Iranmanesh et al. 1994) with a
limit of quantiation (LOQ) of 0.2 ng/mL. Figure 5 (top) displays onentrations
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versus time for the three formulations. There are very few onentrations below LOQ
for the last sampling times.
We analyse the data with NCA and NLMEM using the SAEM algorithm implemented
in MONOLIX 2.4. For NCA analysis, we use the linear trapezoid rule to estimate
AUC0−tlast. To obtain the total AUC, we ompute the terminal slope by log-linear
regression using 2 to 4 sampling times. As desribed in 2.1, the log-transformed indi-
vidual AUC and Cmax are then analysed using a LMEM inluding treatment, period,
sequene, and subjet eets. The referene lasses are the Genotropin
®
treatment,
the rst period, and the sequene Genotropin
®
- Omnitrope
®
powder - Omnitrope
®
solution for the treatment, period, and sequene ovariates, respetively.
For NLMEM analysis, we use a one-ompartment model with rst-order absorption
with a lag time (tlag) and rst-order elimination to desribe the data. With this
model, for sampling times before tlag, onentrations are null. For sampling times
after tlag, onentrations are desribed by Equation 4 replaing t by t − tlag. To de-
termine the struture of the random eets matries and the residual error model,
we analyse the Genotropin
®
data. Models are ompared using the Bayesian Infor-
mation Criteria (BIC), the best statistial model orresponding to the smallest BIC
(Bertrand et al. 2008). For the struture of the BSV matrix, we test diagonal, blok
diagonal, and omplete matries. Regarding the error model, we test a homosedasti
(b = 0) and a ombined error model. For the analysis of all data, the struture of
the WSV matrix is hosen to be idential to the struture of the BSV matrix deter-
mined during the analysis of the Genotropin
®
data. We add treatment, period, and
sequene eets on the four PK parameters. The referene lasses are the same as
for NCA analysis. After tting the data, the model is graphially evaluated using
the individual weighted residuals (IWRES) and the 90% predition interval for eah
formulation. For the model evaluation, from the nal statistial model and its esti-
mates, we simulate 200 datasets based on the struture of the original data (dose,
ovariates). For eah formulation, we ompute the 5% and 95% perentiles of the
simulated time-ourse distribution to obtain the 90% predition interval. The orre-
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spoding graph is alled a Visual Preditive Chek.
We perform bioequivalene Wald tests on AUC and Cmax using NCA and NLMEM
estimates with a type I error of 5%. For NLMEM, we ompute the treatment eet
on Cmax using xed eets estimates and its standard error by the delta method.
4.2 Results
For the analysis of the Genotropin
®
data, the best statistial model inlude BSV
for all PK parameters with a orrelation between the learane and the volume of
distribution, and a ombined error model. Parameter estimates (exept period and
sequene eets) are displayed in Table 3 with their standard errors. Preision of
estimation is judged satisfatory for all parameters. Conentrations of somatropin
versus time with their 90% predition interval and the IWRES versus time are dis-
played in Figure 5 for eah treatment group. These model evaluation plots are judged
satisfatory.
After estimating the parameters by NCA and NLMEM, we perform bioequivalene
Wald tests on AUC and Cmax for both formulations of Omnitrope
®
. The results of
those tests are displayed in Table 4 with the ratios of AUC and Cmax, the orre-
sponding 90% CI, and the p-values of the bioequivalene Wald tests. With a type I
error of 5%, AUC and Cmax of Omnitrope
®
powder and solution are bioequivalent
to those of Genotropin
®
using NCA and NLMEM bioequivalene analysis.
5 DISCUSSION
In this study, we evaluate the type I error of NLMEM-based bioequivalene tests
performed on the treatment eet estimates when treatment, period, and sequene
eets but also within-subjet variability are taken into aount during the NLMEM
estimation. This new approah is ompared to the standard non-ompartmental
analysis where bioequivalene Wald tests are performed on the treatment eet esti-
mated by linear mixed eets model taking into aount the same three ovariates,
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BSV (orresponding to the random subjet eet) and WSV (i.e. residual error).
Conerning the NLMEM-based bioequivalene tests, we show how Wald tests an be
performed on a seondary parameter suh as Cmax whih allows the extension of the
standard bioequivalene analysis based on NCA estimates to the NLMEM ontext.
Furthermore, for a parameter of the PK model, we extend the likelihood ratio test
for bioequivalene.
As Panhard et al (Panhard et al. 2007), and Dubois et al (Dubois et al. 2010), we simu-
late under a one-ompartment PK model and estimate the NLMEM parameters using
the same model. So, we do not study the impat of having the inorret model being
used in the bioequivalene NLMEM-based tests, and how would it ompare to the
NCA approah in that ase. Nevertheless, when bioequivalene analysis is performed,
there is already aumulated information on the drug and the pharmaokineti model
is usually known. Furthermore, even if NCA is known as a "model-free" approah, it
assumes linear terminal elimination and provides meaningless parameters when it is
applied to nonlinear pharmaokinetis. So, the problem of estimating with a "wrong"
model ould exist for NCA and NLMEM.
The NLMEM-based bioequivalene analysis requires to estimate many parameters.
So, a robust algorithm has to be used. The simulation study illustrates the auray
of the SAEM algorithm, espeially in the ontext of bioequivalene analysis. We
show that biases and RMSE obtained by the SAEM algorithm are satisfatory for all
parameters although BSV and WSV are slightly underestimated for large variability
and low number of patients. These results are similar to those obtained by Panhard
and Samson (Panhard and Samson 2009). As expeted, biases and RMSE derease
when the amount of information inreases (by the inrease of the number of patients
or periods). All xed eets are orretly estimated with no bias, whih is of great
interest for testing treatment eet estimates. The good estimation of the xed ef-
fets using the SAEM algorithm leads to a good estimation of the geometri means
of AUC and Cmax, as illustrated by our evaluation. At the opposite, this evaluation
also shows that geometri means estimated by NCA are biased for sparse design,
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espeially with high variability. Usually, NCA is used with rih designs where there
are about ten to twenty samples per subjet. This method is not well suited for trials
performed in patients where the number of samples is often limited. In omparison
to model-based approahes, the estimation of parameters through NCA has several
drawbaks. It is giving equal weight to all onentrations without taking into aount
the measurement error. Furthermore, NCA is sensitive to missing data, espeially for
the determination of Cmax and the omputation of the terminal slope. Even without
missing data, the interpolation of the AUC between the last sampling time and in-
nity is very sensitive to the number of samples used to ompute the terminal slope.
However, even with biased geometri mean, the treatment eet estimated by NCA
are not biased whih partly explains the good results for the type I error.
When the number of samples per subjet is large and the variability is not too high,
tests based on individual NCA estimates remain a good approah sine they are sim-
ple and showed satisfatory properties for both tested parameters. For Cmax and the
sparse design, we expeted an inrease of the type I error beause there is no sampling
time orresponding to the maximal onentration whih is lose to 2 h. But even with
poor geometri mean estimates, the type I error is maintained at the nominal level
of 5%. It ould be explain by the good estimation of the treatment eet estimate
despite the biased geometri mean. Though, for simulation with Sh,h, the global type
I error of AUC is very onservative (0.8%) whih shows the limits of NCA for data
with high residual error.
The type I error of the NLMEM-based bioequivalene Wald test and LRT are rather
similar but Wald tests are easier to perform. Indeed, the bioequivalene LRT requires
to estimate the parameters and log-likelihood of three statistial models. Further-
more, there is urrently no methodology to perform a LRT on a seondary parameter
if the model annot be reparameterized using this parameter (e.g. Cmax). For a Wald
test on Cmax, the delta method or simulations an be used to estimate its treatment
eet standard error. Based on our simulation study, for a one-ompartment PK
model, the use of simulations is not more eient than the delta method. Indeed,
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for eah simulation setting, standard errors estimated by delta method or simulations
are really lose and the results of the type I error are similar for both estimations.
However, the use of the delta method an be triky sine the analytial expression of
Cmax is not always available for omplex or nonlinear PK models.
For NLMEM-based Wald tests and LRT, we found an ination of the type I error
when the onditions move away from asymptoti, i.e. for small sample size and/or
data with high variability. The use of NLMEM-based bioequivalene analysis in its
urrent proposed form would be questionable for regulatory agenies in these ases
due to onerns about potential type I error ination. For NLMEM-based Wald tests,
the underestimation of the standard errors are responsible of the ination of the type
I error. Indeed, there is no ination when the empirial standard error is used instead
of the estimated. The empirial standard error an be used in pratie but not easily
beause of the omputing time. It requires rst to estimate the parameters using
the data of the linial trial of interest, then to simulate trials with the same design
as the original dataset and nally to re-estimate the parameters for eah simulated
trial. This approah also assumes that the underlying strutural model is orret
whih is usually the ase when bioequivalene analysis is performed, as previously
mentionned. In our simulation, the number of subjets is more inuential on the
ination of the type I error than the number of samples. Indeed, there is a slight
ination of the type I error for the sparse design (N = 40, n = 3) ompared to the
rih (N = 40, n = 10, same N) whereas the ination is higher for the original design
(N = 12, n = 10) also ompared to the rih (same n). For NLMEM-based Wald test,
this is explained by the slighter underestimation of the standard errors for the sparse
design. The ination of the type I error for NLMEM-based Wald tests and LRT is
not spei to bioequivalene tests. It is due to the asymptoti properties of these
tests and was also demonstrated for omparison tests by Panhard et al (Panhard and
Mentré 2005) and Wälhby et al (Wählby et al. 2001). Similarly, the underestimation
of the standard errors was also related to the ination of the type I error for ompar-
ison NLMEM-based Wald tests (Bertrand et al. 2009). A good ontrol of the type
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I error for a bioequivalene test with sparse sampling should be therefore possible
by inreasing the number of patients. Furthermore, dierent approahes ould be
explored to orret the type I error ination of NLMEM-based bioequivalene tests.
For NLMEM-based Wald tests, the underestimation of BSV and WSV ould explain
the underestimation of the standard errors. Even though maximum likelihood es-
timation is the standard approah in NLMEM, the variane omponents are often
underestimated for small sample size and high variability. In linear mixed eets mod-
els, the REML estimation is widely implemented, but in NLMEM it has been barely
studied, although the REML proedure may improve the estimation of variane om-
ponents in NLMEM. Meza et al (Meza et al. 2007) developped a REML estimation
proedure for the standard SAEM algorithm. They showed that the SAEM-REML
algorithm redues bias and RMSE of the variane parameter estimates in a simu-
lation study on a simple NLMEM. Further work is needed to propose the REML
estimation proedure for the extended SAEM algorithm developed for rossover trial
analysis.By improving the estimation of variane parameters, the REML estimation
proedure should improve the bioequivalene Wald test. As explained in setion 2.1
and 3.2, for bioequivalene Wald tests based on NCA estimates, the LMEM param-
eters are estimated by REML and both test statistis follow a Student t-distribution
with degrees of freedom depending on the number of subjets. So, we perform the
NLMEM-based bioequivalene Wald tests assuming a Student t-distribution under
H0 with the same number of degrees of freedom as the NCA-based bioequivalene
Wald tests (unshown results). For all simulation settings, the type error dereases
ompared to the NLMEM-based Wald test with a Gaussian distribution but there
is still a slight ination of the type I error while the use of empirial SE orrets it.
To our knowledge, there is no theoritial development or evaluation of the degrees of
freedom in the ontext of NLMEM. The distribution we use is more or less empirial,
and further work is needed.
Other approahes ould be studied suh as the orretion of the nominal level using
permutation tests or bootstrap methods to estimate the 90% CI. However, perform-
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ing a permutation test may not be suitable for bioequivalene, and boostrap methods
have not yet been properly studied in NLMEM. In NLMEM ontext, the paired boot-
strap is usually used but without taking into aount the dierent levels of variability
of the NLMEM. Furthermore, there is no theoritial or simulation result to justify
its appliation. To our knowledge, only two published studies adress the issue of
bootstrap in NLMEM (Das and Krishen 1999; Oaña et al. 2005). Oaña et al (Das
and Krishen 1999) proposed a bootstrap approah resampling the random eets and
residual errors. They evaluated it by simulation but they performed it using two-stage
tting proedure (Steimer et al. 1984) where "population" mean parameters are es-
timated from individual parameters obtained after separate tting of eah subjet
data. Further simulations studies are needed to really understand bootstrap methods
properties in NLMEM. So, we would favor a orretion of the tests by degrees of
freedom, whih is also a less omputer intensive method.
The analysis of the rossover trial of three somatropin formulations shows the ability
to perform a NLMEM-based bioequivalene analysis using the SAEM algorithm on a
real data set. Even with forty xed eets and ten variane parameters in the statis-
tial model, the SAEM algorithm onverges. Furthermore, the SAEM algorithm an
handle data below the limit of quantiation ontrary to NCA. The PK parameter es-
timates for Genotropin
®
are similar to those found by Stanhope et al (Stanhope et al.
2010). We perform NLMEM-based bioequivalene Wald tests and not LRT beause
results on Wald tests and LRT are similar in the simulation study, and we would like
to perform tests on the treatment eets of AUC and Cmax, whih is not possible by
LRT. The results of the bioequivalene analysis based on NCA and NLMEM are sim-
ilar. In both ases, we assess the bioequivalene of both Omnitropee
®
formulations.
Bioequivalene tests based on NLMEM allow one to derease the number of sam-
ples per subjet, whih is of great interest for trials performed in patients. However,
aution is needed for small sample size and data with high variability. With sparse
sampling, the hoie of design is important notably to improve the properties of tests.
For instane, Bertrand et al (Bertrand et al. 2009) showed that, for the same number
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of samples, some designs have better power than others for detetion of a pharmao-
geneti eet in a one-period trial. Design optimisation algorithms for models with
disrete ovariates and dierent periods of treatment ould be used for rossover
studies. They are now available in the version 3.2 of PFIM software (Bazzoli et al.
2010).
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APPENDIX: DELTA METHOD FOR CMAX
For a one-ompartment model with rst-order absorption and rst-order elimation
Cmax is a funtion of the three PK parameters:
Cmax =
FD
V
exp
(
CL log(ka)− log(CL/V )
V ka − CL
)
(5)
So, βTCmax is a funtion h of λka , λV/F , λCL/F , β
T
ka , β
T
V/F , and β
T
CL/F :
βTCmax =h(λka, λV/F , λCL/F , β
T
ka , β
T
V/F , β
T
CL/F )
=− βTV/F − A2
λCL/F exp(β
T
CL/F )
A1
+
λCL/F√
A6
log
(
λkaλV/F
λCL/F
) (6)
The vetor of partial derivatives of h is:
∇h =
(
1
λka
(
A4
A3
− A5
A6
)
, 1
λV/F
(
A4
A3
− A5
A6
)
, 1
λCL/F
(
−A4
A3
+ A5
A6
)
, A4
A3
, A4
A3
− 1, −A4
A3
)
′
(7)
where
A1 =λkaλV/F exp(β
T
ka + β
T
V/F )− λCL/F exp(βTCL/F )
A2 = log
(
λkaλV/F
λCL/F
)
+ βTka + β
T
V/F − βTCL/F
A3 =
(−A1λCL/F exp(βTCL/F ))2
A4 =A3 + A2 λka λV/F λCL/F exp(β
T
ka + β
T
V/F + β
T
CL/F )
A5 =λkaλV/FλCL/F log(λkaλV/F/λCL/F ) + λCL/F (λCL/F − λkaλV/F )
A6 =
(
λkaλV/F − λCL/F
)2
(8)
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Table 1: Bias (×100) and root mean square error (RMSE ×100) of estimates of
referene eets and of standard deviations for BSV, WSV, and residual error.
Period λka λV/F λCL/F ωka ωV/F ωCL/F γka γV/F γCL/F b
N = 40, n = 10
Sl,l 2 bias 0 0 0 -0.2 -0.1 -0.2 -0.1 0 -0.1 0
RMSE 9.2 1.3 0.2 1.3 0.3 1.1 0.6 0.1 0.3 0.4
4 bias -1.1 -0.2 0 -0.2 -0.1 -0.2 -0.1 0 0 0
RMSE 8.7 1.3 0.2 1.1 0.3 1 0.4 0.1 0.2 0.3
Sh,l 2 bias -1.8 -0.5 0 2.7 3.6 -1.2 -0.1 -0.1 -0.2 0.1
RMSE 18.5 5.8 0.5 8.6 8.9 6 1.3 0.7 0.7 0.4
4 bias 0.2 0.2 0 -0.4 -0.4 -1.2 -0.1 -0.1 -0.1 0.1
RMSE 17.9 5.7 0.5 6.1 5.8 5.8 0.7 0.4 0.4 0.3
N = 40, n = 3
Sl,l 2 bias 0.3 -0.1 0 -0.2 -0.1 -0.2 0 0 -0.1 -0.4
RMSE 11 1.7 0.2 1.6 0.4 1.1 0.9 0.3 0.5 1.5
4 bias -0.8 0 0 -0.3 -0.1 -0.2 -0.1 0 0 -0.2
RMSE 9.5 1.6 0.2 1.2 0.3 1 0.6 0.2 0.3 0.9
Sh,l 2 bias 6.9 1.6 -0.1 2.1 -3.2 -4.2 0 -0.3 -0.3 0.3
RMSE 22.8 5.8 0.4 8.9 6.3 6.8 1.9 0.9 1 2.5
4 bias 6.5 1.8 -0.1 2.1 -3.6 -4.2 -0.1 -0.3 -0.2 0.6
RMSE 21.4 5.9 0.4 8.6 6.2 6.5 1.3 0.6 0.6 1.7
NOTE: Bias and RMSE are estimated from 1000 rossover trials simulated under H0;80%
with two or four periods, for the rih (N = 40, n = 10) and sparse (N = 40, n = 3) designs,
and two variability settings (Sl,l and Sh,l).
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Table 2: Type I error (×100) of bioequivalene tests performed on the treatment eet of AUC and Cmax for eah unilateral hypothesis,
H0;80% and H0;125%.
N = 40, n = 10 N = 12, n = 10 N = 24, n = 5 N = 40, n = 3
NCA NLMEM NCA NLMEM NCA NLMEM NCA NLMEM
Wald LRT Wald LRT Wald LRT Wald LRT
Sll AUC H0;80% 4.0 5.3 5.3 5.2 9.3 8.1 4.3 7.0 6.8 5.9 4.8 4.8
H0;125% 5.1 5.2 5.2 5.2 9.3 7.6 3.8 5.8 5.6 5.1 5.6 5.2
Cmax H0;80% 6.6 4.6 (4.7) 5.1 7.3 5.3 5.2 6.8 8.5
H0;125% 6.3 6.8 5.6 8.0 5.2 8.0 5.5 6.9 (6.8)
Sh,l AUC H0;80% 5.4 4.8 5.3 4.4 11.0 10.0 5.2 9 8.2 4.5 6.4 6.0
H0;125% 6.1 6.6 6.0 4.7 10.7 8.9 3.9 6.7 6.8 5.1 8.6 7.2
Cmax H0;80% 5.1 4.9 5.3 9.1 (9.0) 6.0 6.3 (6.2) 7.2 6.9
H0;125% 5.4 5.3 5.1 8.9 6.1 7.0 6.2 6.9
Sh,h AUC H0;80% 0.8 6.0 8.3
H0;125% 0.4 5.8 5.9
Cmax H0;80% 7.0 5.8 (5.3)
H0;125% 9.3 10.3 (9.9)
NOTE: The Wald tests based on NCA and NLMEM estimates are performed on the treatment eet of AUC and Cmax. The NLMEM-based
likelihood ratio test (LRT) is performed on CL/F (i.e. AUC) only. The type I error is estimated from 1000 two-period rossover trials simulated
under H0;80% or H0;125% for dierent sampling designs (N : number of subjets, n: number of samples per subjet and period) and three variability
settings (Sl,l, Sh,l, and Sh,h). For NLMEM-based bioequivalene Wald tests performed on the treatment eet of Cmax, type I errors are estimated
using the delta method or simulations. The values of both type I errors are reported only if they are not equal; in that ase, the type I error of
Cmax from simulations is in brakets.
3
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Table 3: Pharmaokineti parameter estimates of somatropin (standard errors) from
the three-way rossover study on somatropin (period and sequene eets are not
reported).
tlag (h) ka (h
−1
) V/F (L) CL/F (L/h) corrCL/F,V/F
λ 0.46 (0.08) 0.32 (0.05) 25.83 (6.24) 8.66 (0.86)
βTpowder -0.25 (0.08) -0.24 (0.1) -0.14 (0.12) 0.01 (0.03)
βTsolution -0.04 (0.06) -0.11 (0.11) 0.01 (0.13) 0.05 (0.03)
ω 0.38 (0.06) 0.15 (0.08) 0.39 (0.04) 0.23 (0.01) 0.95
γ 0.12 (0.06) 0.27 (0.08) 0.36 (0.04) 0.10 (0.01) 0.67
a (ng/mL) 0.12 (0.02)
b 0.14 (0.004)
NOTE: The referene formulation is the Genotropin
®
. Treatment eets are estimated for
Omnitrope
®
powder (βTpowder) and Omnitrope
®
solution (βTsolution)
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Table 4: Bioequivalene Wald tests using NCA and NLMEM estimates for the three-
way rossover study on somatropin.
NCA NLMEM
Formulation Ratio 90% CI p Ratio 90% CI p
AUC
powder 0.99 [0.94; 1.03℄ 7 10−11 0.99 [0.95; 1.04℄ 3 10−17
solution 0.95 [0.90; 0.99℄ 3 10−8 0.95 [0.92; 1.00℄ 5 10−12
Cmax
powder 0.95 [0.88; 1.03℄ 3 10−4 0.94 [0.84; 1.04℄ 0.008
solution 0.93 [0.86; 1.01℄ 0.001 0.92 [0.83; 1.02℄ 0.015
NOTE: p is the p-value of the bioequivalene Wald test. The referene formulation is the
Genotropin
®
. The ratios orrespond to Omnitrope
®
powder versus Genotropin
®
and to
Omnitrope
®
solution versus Genotropin
®
.
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Legend to gures
Figure 1. Boxplots of the estimates of the learane referene eet (λCL/F ), or-
responding ovariate eets (βTCL/F , β
P
CL/F and β
S
CL/F ), and standard deviation of
the between-subjet (ωCL/F ) and within-subjet (γCL/F ) variability for the hypothe-
sis H0;80%. Parameters are estimated from the 1000 rossover trials simulated under
H0;80% with two or four periods, for the rih (N = 40, n = 10) and sparse (N = 40,
n = 3) designs, and two variability settings, Sl,l (top) and Sh,l (bottom). For four-
period rossover trials, only the period eet estimates β̂P2,CL/F are displayed. The
horizontal lines orrespond to the true simulated values.
Figure 2. Boxplots of the geometri mean estimates of AUC (top) and Cmax (bottom)
estimated by NCA (left) or NLMEM (right), for eah simulation setting of two-period
rossover trials, the hypothesis H0;80%, and the referene treatment. The horizontal
lines orrespond to the geometri means omputed from the NLMEM simulated pa-
rameters.
Figure 3.Boxplots of the treatment eet on AUC (rst row) and Cmax (third row) and
their standard errors (seond and fourth rows) estimated by NCA (left) or NLMEM
(right), for eah simulation setting of two-period rossover trials and the hypothesis
H0;80%. For NCA, β
T
AUC , β̂
T
Cmax
, se(βTAUC) and se(β
T
Cmax
) are obtained from LMEM
analysis. For NLMEM, the estimates of βTAUC and se(β
T
AUC) are diretly obtained
from β̂TCL/F and se(β
T
CL/F ). The treatment eet β̂
T
Cmax is omputed from λ̂ and β̂
T
,
and se(βTCmax) is estimated by the delta method. The horizontal lines orrespond to
the true simulated values of the treatment eets. The ross symbols orrespond to
the empirial standard errors of the treatment eet omputed for eah simulation
setting.
Figure 4. Gobal type I error of the bioequivalene tests performed on the treat-
ment eet of AUC (top) and Cmax (bottom) from NCA (right) and NLMEM (left)
estimates. The Wald tests based on NCA and NLMEM estimates are performed
on both parameters, the likelihood ratio test (LRT) is performed only on AUC.
For NLMEM-based bioequivalene Wald tests, se(βTCmax) are estimated by the delta
38
method. NLMEM-based bioequivalene Wald tests are performed with the estimated
or empirial standard error. The type I error is estimated from 1000 bioequivalene
trials simulated under H0;80% and H0;125% for dierent sampling designs (N : number
of subjets, n: number of samples per subjet) and dierent variability settings Sl,l,
Sh,l, and Sh,h. The horizontal dashed lines represent the nominal level at 5% and its
95% predition interval ([3.7%; 6.4%]).
Figure 5. Observed onentrations of somatropin versus time with their 90% predi-
tion interval (top), and individual weighted residuals (IWRES) versus time (bot-
tom) for eah treatment, Genotropin
®
(left), Omnitrope
®
powder (middle), and
Omnitrope
®
solution (right).
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